INT149861

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.75
First Reported 2008
Last Reported 2010
Negated 1
Speculated 1
Reported most in Body
Documents 14
Total Number 14
Disease Relevance 9.35
Pain Relevance 0.47

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (CD52)
Anatomy Link Frequency
hematopoietic stem cells 2
erythrocytes 2
platelets 2
spinal 1
hindbrain 1
CD52 (Homo sapiens)
Pain Link Frequency Relevance Heat
Central nervous system 6 99.00 Very High Very High Very High
Spinal cord 279 95.24 Very High Very High Very High
addiction 6 87.52 High High
Multiple sclerosis 3 75.00 Quite High
imagery 42 66.68 Quite High
syringomyelia 33 65.80 Quite High
cva 17 45.12 Quite Low
headache 2 27.76 Quite Low
corticosteroid 14 5.00 Very Low Very Low Very Low
Pain 14 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Infection 179 100.00 Very High Very High Very High
Hepatitis A Virus Infection 42 100.00 Very High Very High Very High
Scoliosis 909 99.80 Very High Very High Very High
Hematological Disease 14 99.44 Very High Very High Very High
Prostate Cancer 27 99.36 Very High Very High Very High
Paroxysmal Nocturnal Hemoglobinuria 158 99.16 Very High Very High Very High
Apoptosis 38 98.74 Very High Very High Very High
Cancer 62 96.84 Very High Very High Very High
Neutropenia 64 96.76 Very High Very High Very High
Hepatitis C Virus Infection 21 95.40 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Newer immunosuppressive agents such as the anti-CD52 monoclonal antibody alemtuzumab may be an alternative candidate as immunosuppressant; in this setting, there is no concern about the potential risk of selecting for PNH hematopoiesis, given that the GPI-linked CD52 is not expressed on HSCs.
Neg (not) Gene_expression (expressed) of CD52 associated with hematological disease and paroxysmal nocturnal hemoglobinuria
1) Confidence 0.75 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721357 Disease Relevance 0.92 Pain Relevance 0
Campath 1-H (Alemtuzumab) is a humanised monoclonal antibody which targets the CD52 antigen, a low molecular weight glycoprotein present on the surface of most lymphocyte lineages, causing complement mediated lysis and rapid and prolonged T lymphocyte depletion.
Gene_expression (targets) of CD52 in T lymphocyte
2) Confidence 0.65 Published 2008 Journal J. Neurol. Section Abstract Doc Link 18283404 Disease Relevance 0.26 Pain Relevance 0.07
Sera from a subset of 51 patients with anti-HAV IgM were analysed by anti-HAV IgG avidity assays and HAV PCR.6,7 The AFRIMS ELISA was used to detect IgM and total antibody (Ig) to HEV.8,9 Acute HEV infection was defined as anti-HEV IgM?
Spec (analysed) Gene_expression (analysed) of HEV associated with hepatitis a virus infection and infection
3) Confidence 0.65 Published 2010 Journal Transactions of the Royal Society of Tropical Medicine and Hygiene Section Body Doc Link PMC2896487 Disease Relevance 1.09 Pain Relevance 0
Normal hematopoietic stem cells, erythrocytes and platelets lack CD52 surface expression and are hence protected from drug-induced cytotoxicity.42,43 In contrast, neutrophils were recently reported to express low levels of CD52, which allow complement-mediated lysis and explain previously observed clinical neutropenias under alemtuzumab.44
Gene_expression (expression) of CD52 in platelets associated with neutropenia
4) Confidence 0.24 Published 2010 Journal OncoTargets and therapy Section Body Doc Link PMC2895774 Disease Relevance 0.59 Pain Relevance 0
Normal hematopoietic stem cells, erythrocytes and platelets lack CD52 surface expression and are hence protected from drug-induced cytotoxicity.42,43 In contrast, neutrophils were recently reported to express low levels of CD52, which allow complement-mediated lysis and explain previously observed clinical neutropenias under alemtuzumab.44
Gene_expression (express) of CD52 in platelets associated with neutropenia
5) Confidence 0.24 Published 2010 Journal OncoTargets and therapy Section Body Doc Link PMC2895774 Disease Relevance 0.66 Pain Relevance 0
In vitro synergistic apoptotic effects of combined alemtuzumab plus rituximab or purine analogs have been correlated to complementary activities in the deregulation of pro- or anti-apoptotic molecules such as Bax, Bcl-2.46 Further, an increased surface expression of CD52 after rituximab treatment was observed to initiate alemtuzumab sensitivity in rituximab-resistant cell lines.48 These observations suggest possible clinical benefits from the simultaneous or sequential application of alemtuzumab with these or related drugs in vivo.
Gene_expression (expression) of CD52 associated with apoptosis
6) Confidence 0.21 Published 2010 Journal OncoTargets and therapy Section Body Doc Link PMC2895774 Disease Relevance 0.85 Pain Relevance 0
Normal hematopoietic stem cells, erythrocytes and platelets lack CD52 surface expression and are hence protected from drug-induced cytotoxicity.42,43 In contrast, neutrophils were recently reported to express low levels of CD52, which allow complement-mediated lysis and explain previously observed clinical neutropenias under alemtuzumab.44
Gene_expression (express) of CD52 in hematopoietic stem cells associated with neutropenia
7) Confidence 0.08 Published 2010 Journal OncoTargets and therapy Section Body Doc Link PMC2895774 Disease Relevance 0.66 Pain Relevance 0
Normal hematopoietic stem cells, erythrocytes and platelets lack CD52 surface expression and are hence protected from drug-induced cytotoxicity.42,43 In contrast, neutrophils were recently reported to express low levels of CD52, which allow complement-mediated lysis and explain previously observed clinical neutropenias under alemtuzumab.44
Gene_expression (expression) of CD52 in hematopoietic stem cells associated with neutropenia
8) Confidence 0.08 Published 2010 Journal OncoTargets and therapy Section Body Doc Link PMC2895774 Disease Relevance 0.59 Pain Relevance 0
Normal hematopoietic stem cells, erythrocytes and platelets lack CD52 surface expression and are hence protected from drug-induced cytotoxicity.42,43 In contrast, neutrophils were recently reported to express low levels of CD52, which allow complement-mediated lysis and explain previously observed clinical neutropenias under alemtuzumab.44
Gene_expression (expression) of CD52 in erythrocytes associated with neutropenia
9) Confidence 0.08 Published 2010 Journal OncoTargets and therapy Section Body Doc Link PMC2895774 Disease Relevance 0.59 Pain Relevance 0
Normal hematopoietic stem cells, erythrocytes and platelets lack CD52 surface expression and are hence protected from drug-induced cytotoxicity.42,43 In contrast, neutrophils were recently reported to express low levels of CD52, which allow complement-mediated lysis and explain previously observed clinical neutropenias under alemtuzumab.44
Gene_expression (express) of CD52 in erythrocytes associated with neutropenia
10) Confidence 0.08 Published 2010 Journal OncoTargets and therapy Section Body Doc Link PMC2895774 Disease Relevance 0.66 Pain Relevance 0
A double pathology?
Gene_expression (double) of pathology
11) Confidence 0.06 Published 2008 Journal Scoliosis Section Body Doc Link PMC2474583 Disease Relevance 0.83 Pain Relevance 0.08
Is there a dual spinal pathology?
Gene_expression (dual) of pathology in spinal
12) Confidence 0.06 Published 2008 Journal Scoliosis Section Body Doc Link PMC2474583 Disease Relevance 0.70 Pain Relevance 0.24
a) the view that pontine and hindbrain regions are the likely sites of primary pathology that could lead to idiopathic scoliosis [94],
Gene_expression (sites) of pathology in hindbrain associated with scoliosis
13) Confidence 0.06 Published 2008 Journal Scoliosis Section Body Doc Link PMC2474583 Disease Relevance 0.51 Pain Relevance 0.03
In this study, we constructed and analyzed a mathematical model of the integration between hormone growth factor signaling, androgen receptor activation, and the expression of cyclin D and Prostate-Specific Antigen in human LNCaP prostate adenocarcinoma cells.
Gene_expression (expression) of Antigen associated with prostate cancer
14) Confidence 0.01 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC2812491 Disease Relevance 0.43 Pain Relevance 0.04

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox